Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IDXX 
IDEXX Laboratories Inc (IDXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: IDXX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $697.17
1 Year Target Price $697.17
| 3 | Strong Buy |
| 3 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.79% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 50.67B USD | Price to earnings Ratio 52.65 | 1Y Target Price 697.17 |
Price to earnings Ratio 52.65 | 1Y Target Price 697.17 | ||
Volume (30-day avg) 13 | Beta 1.58 | 52 Weeks Range 356.14 - 688.12 | Updated Date 10/13/2025 |
52 Weeks Range 356.14 - 688.12 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 12.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 24.41% | Operating Margin (TTM) 33.62% |
Management Effectiveness
Return on Assets (TTM) 23.26% | Return on Equity (TTM) 64.87% |
Valuation
Trailing PE 52.65 | Forward PE 44.64 | Enterprise Value 51782852244 | Price to Sales(TTM) 12.55 |
Enterprise Value 51782852244 | Price to Sales(TTM) 12.55 | ||
Enterprise Value to Revenue 12.82 | Enterprise Value to EBITDA 37 | Shares Outstanding 80004694 | Shares Floating 79117442 |
Shares Outstanding 80004694 | Shares Floating 79117442 | ||
Percent Insiders 0.68 | Percent Institutions 97.4 |
Upturn AI SWOT
IDEXX Laboratories Inc
Company Overview
History and Background
IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine. It began with developing and marketing diagnostic tests for animal health and has grown into a global leader in pet healthcare innovation, providing diagnostics and software to veterinary practices worldwide.
Core Business Areas
- CAG Diagnostics: Offers diagnostic products and services for companion animals, including in-clinic diagnostic instruments, reference laboratory services, and rapid assay tests. This is their largest segment.
- Water: Develops and manufactures products used to test water for microbiological and chemical contaminants.
- Livestock, Poultry and Dairy (LPD): Provides diagnostic tests for livestock, poultry, and dairy animals to help manage animal health and food safety.
Leadership and Structure
IDEXX Laboratories is led by Jay Mazelsky (President and CEO). The organizational structure is departmentalized, with divisions focusing on each of the core business areas.
Top Products and Market Share
Key Offerings
- Catalyst Dx Chemistry Analyzer: In-clinic chemistry analyzer used to run blood tests. IDEXX holds a significant market share in this area, estimated above 50%. Competitors: Zoetis, Heska (now part of Mars).
- VetConnect PLUS: Software platform integrating diagnostics data and practice management. Competitors include cloud-based practice management software.
- SNAP Tests: Rapid immunoassay tests for various animal diseases. Estimated above 40% of market share. Competitors: Zoetis, Heska (now part of Mars).
Market Dynamics
Industry Overview
The animal health diagnostics industry is growing, driven by increasing pet ownership, higher spending on pet healthcare, and technological advancements in diagnostics.
Positioning
IDEXX is a leading player, known for its innovative diagnostic solutions and its integrated service offerings, creating a robust competitive edge.
Total Addressable Market (TAM)
The global animal health market is expected to exceed $75 billion by 2030. IDEXX is well positioned to capture a significant portion of this market due to its strong presence in diagnostics.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Extensive product portfolio
- Global presence
- Innovative technology
- High customer loyalty
Weaknesses
- High dependence on companion animal diagnostics
- Premium pricing may limit affordability for some customers
- Geographic concentration of manufacturing
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests for livestock
- Further integrating diagnostics with telemedicine
- Partnerships and acquisitions to expand product offerings
Threats
- Intense competition
- Economic downturn affecting pet spending
- Regulatory changes in diagnostic testing
- Disruptive technologies from new entrants
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- ZTS
- VET
- ELAN
Competitive Landscape
IDEXX's competitive advantages include its integrated diagnostic solutions, strong brand reputation, and global presence. Disadvantages include premium pricing compared to some competitors.
Major Acquisitions
ezyVet
- Year: 2021
- Acquisition Price (USD millions): 210
- Strategic Rationale: The acquisition of ezyVet, a cloud-based practice management software, strengthens IDEXX's software offerings and integrates diagnostics data with practice workflows.
Growth Trajectory and Initiatives
Historical Growth: IDEXX has demonstrated consistent revenue and earnings growth over the past decade, driven by increasing pet ownership and veterinary spending.
Future Projections: Analysts project continued revenue growth in the high single digits, driven by new product launches and expansion into emerging markets.
Recent Initiatives: Recent initiatives include expanding reference laboratory services, launching new diagnostic tests, and investing in digital technologies.
Summary
IDEXX is a strong company with a leading position in the animal health diagnostics market. Its growth is driven by innovation and increasing pet healthcare spending. Key strengths include its brand and integrated solutions, while potential threats involve competition and economic conditions. The company should be prepared for economic downturn and further expand to global markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available information and is for informational purposes only. It should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IDEXX Laboratories Inc
Exchange NASDAQ | Headquaters Westbrook, ME, United States | ||
IPO Launch date 1991-06-21 | President, CEO & Director Mr. Jonathan J. Mazelsky | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.idexx.com |
Full time employees 11000 | Website https://www.idexx.com | ||
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.